



Docket No. ORT 1222 (DIV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : McComsey et al

Serial No. : 10/606,422

Art Unit: 6306

Filed : June 26, 2003

Examiner: LUKTON, DAVID

For : SUBSTITUTED HETEROCYCLIC ACYL-TRIPEPTIDES USEFUL  
AS THROMBIN RECEPTOR MODULATORS

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

FEBRUARY 10, 2006

(Date of Deposit)

YURIY P. STERCHO, PH.D.

(Name of applicant, assignee, or Registered Representative)

  
(Signature)

FEBRUARY 10, 006

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Washington, D.C. 20231

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure  
Statement mailed on January 18, 2005.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-  
identified application is hereby disclosed. Inclusion of  
information in this statement is not to be construed as an  
admission that this information is material as that term is  
defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the  
patentability of the claimed invention over any of the  
information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ORT1222 (Div)/YS the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☒ Please charge Deposit Account No. 10-0750/ORT1222 (DIV)/YS the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:


☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed January 18, 2005.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT 1222 (DIV)/YS. This form is submitted in triplicate.

Respectfully submitted,

  
YURIY P. STERCHO PH.D.  
Reg. No. 33,797  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(610) 240-8006  
DATED: FEBRUARY 10, 2006

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LINDE ET AL, "Pharmacological treatment for prevention of restenosis" EXPERT OPINION, 2001, pp 281-302, ASHLEY PUBLICATIONS, WWW.ashley-pub.com, CANADA.	
		ISCHINGER, THOMAS, "Antithrombotics in Interventional Cardiology: Optimizing Treatment and Strategies", 1998, pp 25L-28L, VOL. 28 (5B), EXCERPTA MEDICA, INC., THE AMERICAN JOURNAL OF CARDIOLOGY.	
		SCHWARTZ, ROBERT, "Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling", EXCERPTA MEDICA, INC., A SYMPOSIUM: INTERVENTIONAL VASCULAR MEDICINE, 1998, PP14E-17E.	
		MARX ET AL, "Rampamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells" CIRCULATION RESEARCH, 1995 AMERICAN HEART ASSOCIATION, INC. 1995, VOL 76, pp 412-417.	
		SOLLOTT ET AL, "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty In the Rat" THE JOURNAL OF CLINICAL INVESTIGATION, INC., APRIL 1995, pp1869-1876, THE JOURNAL OF CLINICAL INVESTIGATION, INC., VOL. 95, pp 1869-1876.	
		SUZUKI ET AL, "STENT-BASED DELIVERY OF SIROLIMUS REDUCES NEOINTIMAL FORMATION IN A PORCINE CORONARY MODEL" 2001 AMERICAN HEART ASSOCIATION, pp 1188-1193, USA.	
		ANDRADE-GORDON ET AL, "ADMINSTRATION OF A POTENT ANTAGONIST OF PROTEASE-ACTIVATED RECEPTOR-1 (PAR-1) ATTENUATES VASCULAR RESTENOSIS FOLLOWING BALLOON ANGIOPLASTY IN RATS", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298: No. 1, pp 34-42, USA.	
		DERIAN, CLAUDIA ET AL, "BLOCKAGE OF THE THROMBIN RECEPTOR PROTEASE-ACTIVATED RECEPTOR-1 WITH A SMALL-MOLECULE ANTAGONIST PREVENTS THROMBUS FORMATION AND	

		VASCULAR OCCLUSION IN NON-HUMAN PRIMATES" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS" 2003, PP 855-861, vol. 304, THE AMERICAN SOCIETY OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS.	
		CHESEBRO ET AL, "ANTITHROMBOTIC THERAPY AND PROGRESSION OF CORONARY ARTERY DISEASE, ANTIPLATELET VS. ANTITHROMBINS", CIRCULATION, 1992, 86[suppl III]: III-100-III-111]	
		WHITE, HARVEY, "NEWER ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROMES" CARDIOLOGY DEPT. GREEN LANE HOSPITAL, NEW ZEALAND, e-mail: harveyw@ahsl.co.nz, 1999, MOSBY, INC..	
		VERSTRAETE ET AL, "NOVEL ANTITHROMBOTIC DRUGS IN DEVELOPMENT" , CENTER FOR MOLECULAR AND VASCULAR BIOLOGY, UNIVERSITY OF LEUVEN, BELGIUM, DRUGS, 1995, pp 856-884, Adis International Limited.	
		WEKSLER, BABETTE, "ANTIPLATELET AGENTS IN STROKE PREVENTION" DEPT. OF MEDICINE, NEW YORK PRESBYTERIAN HOSPITAL-WEILL CORNELL MEDICAL CENTER, NEW YORK, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journals/ced.	
		MOUSA, SHAKER, "ANTIPLATELET THERAPIES: FROM ASPIRIN TO GPIIb/IIIa-RECEPTOR ANTAGONISTS AND BEYOND" THERAPEUTIC FOCUS, ELSEVIER SCIENCE LTD, 1999, PP 552-560, vol. 4, No. 12, USA.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--